JERUSALEM - The coronavirus variant discovered in South Africa may "carry through" Pfizer / BioNTech's COVID-19 vaccine to some degree, according to a real-world data study in Israel, although its prevalence in the country is low and research has not been peer-reviewed.
The study, published Saturday, compared nearly 400 people who had tested positive for COVID-19, 14 days or more after receiving one or two doses of the vaccine against the same number of unvaccinated patients with the disease. It matched, among other…